Billionaire Cohen Dumps Tech Giants for Cannabis Healthcare Play

Billionaire hedge fund manager Steve Cohen has executed a dramatic portfolio pivot, liquidating major positions in technology darlings Amazon and Nvidia to concentrate capital in the battered cannabis healthcare sector. The Point72 Asset Management chief's move signals growing institutional confidence in cannabis medical applications despite persistent regulatory headwinds and sector-wide valuation compression.

Cohen's strategic reallocation comes as cannabis healthcare companies trade at historic discounts, with many medical-focused operators down 60-80% from 2021 peaks. The timing appears calculated, as federal rescheduling discussions gain momentum and clinical trial data strengthens the medical cannabis investment thesis. Point72's entry provides crucial institutional validation for a sector that has struggled to attract mainstream Wall Street capital.

The healthcare angle represents a sophisticated play on cannabis normalization without direct exposure to recreational market volatility. Medical cannabis companies benefit from more stable regulatory frameworks, insurance reimbursement potential, and pharmaceutical partnership opportunities. Cohen's bet suggests institutional investors view current valuations as disconnected from long-term medical market potential.

This institutional rotation away from overvalued tech stocks toward undervalued cannabis healthcare reflects broader portfolio rebalancing trends. Cannabis medical companies offer compelling risk-adjusted returns at current levels, particularly those with FDA trial pathways or pharmaceutical partnerships. The sector's institutional adoption could accelerate as more hedge funds follow Cohen's lead.

Cohen's move validates the cannabis healthcare investment thesis at a critical inflection point. With federal policy evolution and expanding medical research, institutional capital deployment could trigger sector-wide revaluation. Point72's backing provides both capital and credibility that cannabis healthcare companies need to advance clinical programs and scale operations effectively.